65 studies (2 from unattributed sources) on Cagrilintide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
| Manufacturer | Batches | Avg purity | |
|---|---|---|---|
| Nexaph | 15 | 99.3% | View COA → |
| Peptaris | 14 | 99.66% | View COA → |
| Shanghai Sigma Audley Ssa | 14 | 98.85% | View COA → |
| Hxnet | 14 | 98.58% | View COA → |
| Wuhan Wansheng Biotechnology | 14 | 98.57% | View COA → |
| Unknown vendor (review) | 11 | 99.75% | View COA → |
| GYC | 11 | 99.49% | View COA → |
| Sry Labs | 11 | 99.34% | View COA → |
Recent certificates: #27960 (99.77%) · #24274 (99.54%) · #41479 (99.95%) · #48950 (99.54%) · #53499 (99.54%) · #54256 (99.95%)
Manufacturers with published third-party certificates of analysis for Cagrilintide. Open a vendor to see every batch we've verified.
This meta-analysis provides compelling evidence that CagriSema, combining a GLP-1 receptor agonist (semaglutide) with an amylin analog (cagrilintide), offers a substantially more potent and effective treatment option …
While specific pharmacokinetic data (e.g., Cmax, AUC values) are not detailed in this record, the study successfully completed its Phase 1 objectives, enrolling 40 participants and evaluating the drug exposures over a…
The initiation of this Phase 1 trial is a significant step in the development of new treatments for obesity and overweight, conditions with a substantial global health burden. If NNC0174-1213 demonstrates a favorable …
Treatment with Cagrilintide resulted in profound and statistically significant reductions in body weight and substantial improvements across multiple metabolic markers. > The high-dose Cagrilintide group exhibited a r…
This comprehensive review underscores amylin's critical, yet often underutilized, potential as a therapeutic agent for diabesity. Its unique mechanisms, including appetite suppression and improved glucose regulation, …
This review underscores the critical and enduring role of bariatric surgery as the most efficacious treatment for obesity, even amidst the revolutionary advancements in GLP-1 RA pharmacotherapy. Recognizing the unique…
The development of Amylin-LP1 represents a significant advancement in the therapeutic landscape for metabolic disorders, offering a potent and well-tolerated option. Its long-acting profile could greatly enhance patie…
Cagrisema represents a highly potent and promising new therapeutic option for individuals struggling with obesity, offering superior weight loss efficacy and improved metabolic parameters compared to current gold-stan…
Understanding drug-drug interactions is paramount for patient safety, especially with the increasing use of novel weight-loss medications like CagriSema. Many patients with obesity rely on medications such as atorvast…
As this study is currently "NOT_YET_RECRUITING" and is scheduled to begin in 2026, no results or specific data are available at this time. The primary objective is to determine if there are significant differences in …
The findings from this trial could have a profound impact on the treatment landscape for Type 2 Diabetes. If CagriSema demonstrates superior or even comparable efficacy with a favorable safety profile, it could become…
The successful outcome of this Phase III trial could represent a significant advancement in the treatment landscape for obesity, potentially offering a more effective therapeutic option than current monotherapies. Cag…
As this is a planned study, no results are available yet. However, the researchers anticipate that CagriSema will demonstrate significant improvements in key metabolic markers compared to placebo.
Free, no account — handy when you're working with Cagrilintide.